Study of Viral Transduction of Human Auditory Sensory Cells for the Development of Gene Therapy (TREATGENE)
Gene therapy is a promising strategy to treat hearing loss and vestibular disorders, and Associated adenovirus (AAV) is shown as a good viral vector for inner ear therapy in animal models.
This study aims to study in vitro viral transduction of AAV in human inner ear cells, collected during non-conservative surgeries for vestibular schwannoma.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ghizlene Lahlou
- Phone Number: 33 1 45688891
- Email: ghizlene.lahlou@pasteur.fr
Study Contact Backup
- Name: Saaid Safieddine
- Email: saaid.safieddine@pasteur.fr
Study Locations
-
-
Ile De France
-
Le Kremlin-Bicêtre, Ile De France, France, 94270
- Recruiting
- Hopital de Bicetre
-
Contact:
- Jérôme Nevoux, MD
- Email: jerome.nevoux@aphp.fr
-
Principal Investigator:
- Jérôme Nevoux, MD
-
Paris, Ile De France, France, 75015
- Recruiting
- Hôpital Pitié-Salpêtrière
-
Contact:
- Yann Nguyen, MD
- Email: yann.nguyen@aphp.fr
-
Principal Investigator:
- Yann Nguyen, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient ≥ 18 years old
- Operative indication for a non-conservative resection of vestibular schwannoma, decided by the surgeon in accordance with the patient
- Informed consent obtained
- Patients with a french social protection (AME excluded)
Exclusion Criteria:
- Intravestibular or intra-cochlear extension of the tumor
- Pregnant woman
- Patient with administrative control
- Medical contra-indication
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
AAV viral transduction
Collection of inner ear cells during a non-conservative surgical approach (translabyrinthine or transotic).
|
After obtaining an informed consent during the preoperative medical visit, and if a non-conservative approach (translabyrinthine or transotic) is decided, the collect of inner ear cells will be performed during surgical approach. The sample will be collect in a sterile tube, and carried to the laboratory were it will be placed bon cell culture. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AAV transduction in inner ear cells
Time Frame: 10 days
|
The transduction will be measured with immunostaining techniques
|
10 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Ghizlene Lahlou, Institut Pasteur
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2017-081
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hearing Loss, Sensorineural
-
NCT05154188Not yet recruitingSensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound
-
NCT06699797Active, not recruitingSensorineural Hearing Loss | Sensorineural Hearing Loss (Disorder) | Sensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound | Sensori-Neural Deafness
-
NCT01529333UnknownMixed Conductive and Sensorineural Hearing Loss, Bilateral
-
NCT03509974CompletedUnilateral Mixed Conductive and Sensorineural Hearing Loss (Diagnosis) | Sensorineural Hearing Loss, Unilateral With Normal Hearing on the Contralateral Side
-
NCT04108598UnknownSensorineural Hearing Loss | Sensory Hearing Loss | Sensorineural Hearing Loss in Left Ear | Sensorineural Hearing Loss in Right Ear | Sensorineural Hearing
-
NCT05300230RecruitingBilateral Sensorineural Hearing Loss | Unilateral Sensorineural Hearing Loss
-
NCT05196022RecruitingHearing Loss, Unilateral | Cochlear Implants | Hearing Loss, Sensorineural, Severe | Hearing Loss, Sensorineural, Bilateral | Hearing Loss, Sensorineural, Profound
-
NCT06997406Not yet recruitingTinnitus | Sudden Sensorineural Hearing Loss (SSNHL)
-
NCT06878599Not yet recruitingSudden Sensorineural Hearing Loss (SSNHL)
-
NCT02809118TerminatedHearing Loss, Idiopathic Sudden Sensorineural
Clinical Trials on Peroperative collect of inner ear cells
-
NCT03189433TerminatedDrug Toxicity Psychotropic Agents Psychostimulants
-
NCT02592330CompletedLimbal Stem Cell Deficiency
-
NCT05455398Recruiting